LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q2 17 Estimate To -0.73 From -0.68 5/24/2017 4:54:22 PM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Ourperform With $36 Up From $34 Price Target 5/24/2017 4:53:10 PM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $34 Price Target 4/3/2017 10:09:17 AM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $31 Price Target 2/23/2017 12:34:28 PM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $31 Price Target 12/16/2016 7:35:29 AM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform 12/1/2016 9:00:29 AM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $31 Price Target 10/20/2016 10:44:45 AM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2017 Estimate To -1.83 From -2.34 10/20/2016 10:43:39 AM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 4Q17 Estimate To -0.46 From -0.59 10/20/2016 10:43:21 AM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 3Q17 Estimate To -0.46 From -0.59 10/20/2016 10:43:14 AM
  • Wedbush Is Raising Ascendis Pharma A/S (ASND) 2Q17 Estimate To -0.4600 From -0.5800 10/20/2016 10:42:51 AM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 1Q17 Estimate To -0.45 From -0.58 10/20/2016 10:42:36 AM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2016 Estimate To -2.35 From -2.52 10/20/2016 10:42:20 AM
  • Wedbush Is Raising Ascendis Pharma A/S (ASND) 4Q16 Estimate To -0.46 From -0.59 10/20/2016 10:42:05 AM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $34 Price Target 10/3/2016 7:43:49 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap